Zevin Asset Management LLC Sells 4,689 Shares of AstraZeneca PLC (NASDAQ:AZN)

Zevin Asset Management LLC lowered its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 3.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 148,186 shares of the company's stock after selling 4,689 shares during the quarter. AstraZeneca comprises approximately 1.7% of Zevin Asset Management LLC's investment portfolio, making the stock its 27th biggest holding. Zevin Asset Management LLC's holdings in AstraZeneca were worth $10,892,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Dynamic Advisor Solutions LLC increased its stake in AstraZeneca by 58.4% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company's stock worth $960,000 after purchasing an additional 4,811 shares in the last quarter. Geode Capital Management LLC increased its stake in AstraZeneca by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 498,831 shares of the company's stock worth $32,683,000 after purchasing an additional 5,384 shares in the last quarter. Brandywine Global Investment Management LLC purchased a new position in AstraZeneca in the 4th quarter worth about $28,071,000. Farther Finance Advisors LLC increased its stake in AstraZeneca by 13.1% in the 1st quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company's stock worth $442,000 after purchasing an additional 706 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in AstraZeneca by 1.8% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 311,600 shares of the company's stock worth $22,903,000 after purchasing an additional 5,557 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

AstraZeneca Stock Up 3.6%

Shares of AstraZeneca stock traded up $2.52 on Wednesday, reaching $73.00. 5,020,382 shares of the company were exchanged, compared to its average volume of 5,284,256. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The company has a 50-day moving average of $70.96 and a 200 day moving average of $71.02. The company has a current ratio of 0.90, a quick ratio of 0.70 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $226.40 billion, a price-to-earnings ratio of 29.32, a PEG ratio of 1.30 and a beta of 0.37.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.14. The firm had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The company's quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.06 EPS. On average, equities research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AZN. Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a research report on Wednesday, July 9th. BNP Paribas started coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, AstraZeneca presently has a consensus rating of "Moderate Buy" and an average target price of $89.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.